Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$46.3 million.

  • Coherus Oncology's Free Cash Flow rose 2527.9% to -$46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.5 million, marking a year-over-year increase of 13430.8%. This contributed to the annual value of -$20.4 million for FY2024, which is 8833.13% up from last year.
  • Latest data reveals that Coherus Oncology reported Free Cash Flow of -$46.3 million as of Q3 2025, which was up 2527.9% from $436.8 million recorded in Q2 2025.
  • Coherus Oncology's Free Cash Flow's 5-year high stood at $436.8 million during Q2 2025, with a 5-year trough of -$100.0 million in Q4 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$37.5 million (2022), whereas its average is $5.8 million.
  • As far as peak fluctuations go, Coherus Oncology's Free Cash Flow plummeted by 834394.69% in 2022, and later surged by 35562.99% in 2024.
  • Coherus Oncology's Free Cash Flow (Quarter) stood at -$52.8 million in 2021, then crashed by 89.51% to -$100.0 million in 2022, then soared by 87.03% to -$13.0 million in 2023, then surged by 320.55% to $28.6 million in 2024, then crashed by 261.98% to -$46.3 million in 2025.
  • Its Free Cash Flow was -$46.3 million in Q3 2025, compared to $436.8 million in Q2 2025 and -$30.5 million in Q1 2025.